Adocia SA (ADOC.PA)
EUR 3.85
(2.67%)
EUR 3.85
(2.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -17.62 Million EUR | -938.42% |
| 2022 | -1.69 Million EUR | 91.24% |
| 2021 | -19.36 Million EUR | 8.43% |
| 2020 | -21.14 Million EUR | 3.96% |
| 2019 | -22.02 Million EUR | -326.86% |
| 2018 | 9.7 Million EUR | 122.83% |
| 2017 | -42.52 Million EUR | -431.48% |
| 2016 | -8 Million EUR | -179.19% |
| 2015 | 10.1 Million EUR | 158.87% |
| 2014 | -17.16 Million EUR | -298.91% |
| 2013 | -4.3 Million EUR | 29.13% |
| 2012 | -6.07 Million EUR | 0.07% |
| 2011 | -6.07 Million EUR | -30.99% |
| 2010 | -4.63 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -9.71 Million EUR | 0.0% |
| 2023 Q2 | -9.55 Million EUR | -161.74% |
| 2023 Q3 | -3.47 Million EUR | 63.64% |
| 2023 Q4 | -8.07 Million EUR | -132.43% |
| 2023 Q1 | -3.64 Million EUR | 65.74% |
| 2023 FY | -17.62 Million EUR | -938.42% |
| 2022 Q1 | -2.54 Million EUR | 79.15% |
| 2022 Q2 | -8.15 Million EUR | -220.53% |
| 2022 Q3 | -3.9 Million EUR | 52.17% |
| 2022 Q4 | -10.65 Million EUR | -172.93% |
| 2022 FY | -1.69 Million EUR | 91.24% |
| 2021 Q1 | -4.82 Million EUR | 63.06% |
| 2021 Q3 | -4.86 Million EUR | 58.67% |
| 2021 Q4 | -12.21 Million EUR | -151.11% |
| 2021 FY | -19.36 Million EUR | 8.43% |
| 2021 Q2 | -11.76 Million EUR | -144.11% |
| 2020 FY | -21.14 Million EUR | 3.96% |
| 2020 Q1 | -5.57 Million EUR | 51.9% |
| 2020 Q2 | -14.09 Million EUR | -152.98% |
| 2020 Q4 | -13.04 Million EUR | -160.8% |
| 2020 Q3 | -5 Million EUR | 64.49% |
| 2019 Q2 | -16.43 Million EUR | -145.46% |
| 2019 FY | -22.02 Million EUR | -326.86% |
| 2019 Q4 | -11.58 Million EUR | -168.35% |
| 2019 Q3 | -4.31 Million EUR | 73.73% |
| 2019 Q1 | -6.69 Million EUR | -484.05% |
| 2018 Q1 | 7.16 Million EUR | 192.63% |
| 2018 Q4 | 1.74 Million EUR | 0.0% |
| 2018 FY | 9.7 Million EUR | 122.83% |
| 2018 Q3 | 1.74 Million EUR | -75.66% |
| 2018 Q2 | 7.16 Million EUR | 0.0% |
| 2017 FY | -42.52 Million EUR | -431.48% |
| 2017 Q4 | -7.73 Million EUR | 0.0% |
| 2017 Q3 | -7.73 Million EUR | -312.38% |
| 2017 Q2 | 3.64 Million EUR | 0.0% |
| 2017 Q1 | 3.64 Million EUR | 289.93% |
| 2016 Q2 | -2.08 Million EUR | 0.0% |
| 2016 Q3 | -1.91 Million EUR | 8.04% |
| 2016 Q1 | -2.08 Million EUR | -178.83% |
| 2016 Q4 | -1.91 Million EUR | 0.0% |
| 2016 FY | -8 Million EUR | -179.19% |
| 2015 Q4 | 2.64 Million EUR | 0.0% |
| 2015 FY | 10.1 Million EUR | 158.87% |
| 2015 Q3 | 2.64 Million EUR | 9.78% |
| 2015 Q2 | 2.4 Million EUR | 0.0% |
| 2015 Q1 | 2.4 Million EUR | 141.51% |
| 2014 Q1 | -2.78 Million EUR | -1706.94% |
| 2014 Q3 | -5.8 Million EUR | -108.67% |
| 2014 Q4 | -5.8 Million EUR | 0.0% |
| 2014 FY | -17.16 Million EUR | -298.91% |
| 2014 Q2 | -2.78 Million EUR | 0.0% |
| 2013 Q1 | -2.32 Million EUR | -7.92% |
| 2013 Q2 | -2.32 Million EUR | 0.0% |
| 2013 Q3 | 173 Thousand EUR | 107.44% |
| 2013 Q4 | 173 Thousand EUR | 0.0% |
| 2013 FY | -4.3 Million EUR | 29.13% |
| 2012 FY | -6.07 Million EUR | 0.07% |
| 2012 Q4 | -2.15 Million EUR | 0.0% |
| 2012 Q3 | -2.15 Million EUR | 0.0% |
| 2011 FY | -6.07 Million EUR | -30.99% |
| 2010 FY | -4.63 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -416.471% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 86.165% |
| Aelis Farma SA | -6.46 Million EUR | -172.744% |
| Biophytis S.A. | -14.33 Million EUR | -22.947% |
| Advicenne S.A. | -6.45 Million EUR | -172.913% |
| genOway Société anonyme | 2.06 Million EUR | 953.243% |
| IntegraGen SA | -183.77 Thousand EUR | -9489.16% |
| Medesis Pharma S.A. | -4.22 Million EUR | -316.661% |
| Neovacs S.A. | -6.9 Million EUR | -155.112% |
| NFL Biosciences SA | -4.43 Million EUR | -297.75% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -2164.349% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -461.701% |
| Sensorion SA | -22.31 Million EUR | 21.015% |
| Theranexus Société Anonyme | -7.64 Million EUR | -130.543% |
| TME Pharma N.V. | -5.62 Million EUR | -213.336% |
| Valbiotis SA | -7.16 Million EUR | -146.117% |
| TheraVet SA | -2.17 Million EUR | -710.166% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 13.141% |
| DBV Technologies S.A. | -85.24 Million EUR | 79.328% |
| Genfit S.A. | -26.58 Million EUR | 33.702% |
| GeNeuro SA | -14.35 Million EUR | -22.739% |
| Innate Pharma S.A. | -12.66 Million EUR | -39.095% |
| Inventiva S.A. | -102.7 Million EUR | 82.843% |
| MaaT Pharma SA | -19.94 Million EUR | 11.638% |
| MedinCell S.A. | -20.97 Million EUR | 15.994% |
| Nanobiotix S.A. | -26.77 Million EUR | 34.195% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 23.336% |
| Poxel S.A. | -28.76 Million EUR | 38.736% |
| GenSight Biologics S.A. | -29.69 Million EUR | 40.659% |
| Transgene SA | -30.01 Million EUR | 41.283% |
| Valneva SE | -82.08 Million EUR | 78.533% |